{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:53:45Z","timestamp":1789088025418,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1100904"],"award-info":[{"award-number":["2021YFA1100904"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2507800"],"award-info":[{"award-number":["2023YFC2507800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270224"],"award-info":[{"award-number":["82270224"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200169"],"award-info":[{"award-number":["82200169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270162"],"award-info":[{"award-number":["82270162"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["21WQ034"],"award-info":[{"award-number":["21WQ034"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7222175"],"award-info":[{"award-number":["7222175"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009580","name":"General Hospital of People\u2019s Liberation Army","doi-asserted-by":"publisher","award":["22QNFC021"],"award-info":[{"award-number":["22QNFC021"]}],"id":[{"id":"10.13039\/501100009580","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20230484407"],"award-info":[{"award-number":["20230484407"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["2023hqzz09"],"award-info":[{"award-number":["2023hqzz09"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cpt.2025.12.001","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T17:11:23Z","timestamp":1766423483000},"page":"230-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD)"],"prefix":"10.1016","volume":"4","author":[{"given":"Kun","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0218-0208","authenticated-orcid":false,"given":"Shuangyi","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7093-0476","authenticated-orcid":false,"given":"Yujun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8788-2517","authenticated-orcid":false,"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3334-9113","authenticated-orcid":false,"given":"Daihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2025.12.001_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrc2804","article-title":"Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer","volume":"10","author":"Jenq","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cpt.2025.12.001_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cpt.2025.12.001_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41409-019-0548-7","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities","volume":"55","author":"Al Hamed","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.12.001_bib4","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2025.12.001_bib5","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cpt.2025.12.001_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.107005","article-title":"Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease","volume":"125","author":"Lebon","year":"2023","journal-title":"Leuk Res"},{"key":"10.1016\/j.cpt.2025.12.001_bib7","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2025.12.001_bib8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/16078454.2021.1945234","article-title":"Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms","volume":"26","author":"Duan","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.cpt.2025.12.001_bib9","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1002\/ajh.24688","article-title":"Varicella-zoster virus meningoencephalitis in a patient treated with ruxolitinib","volume":"92","author":"Eyal","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpt.2025.12.001_bib10","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/hon.2769","article-title":"Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib","volume":"38","author":"Rumi","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.cpt.2025.12.001_bib11","article-title":"Epstein-Barr-Virus-Related lymphoproliferative disorder in a patient with primary myelofibrosis: a case report and literature review","volume":"16","author":"Oshima","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.cpt.2025.12.001_bib12","doi-asserted-by":"crossref","first-page":"75 e1","DOI":"10.1016\/j.bbmt.2020.09.015","article-title":"Ruxolitinib combined with corticosteroids as first-line therapy for acute graft-versus-host disease in haploidentical peripheral blood stem cell transplantation recipients","volume":"27","author":"Hou","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.cpt.2025.12.001_bib13","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00277-019-03742-7","article-title":"Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies","volume":"98","author":"Gao","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cpt.2025.12.001_bib14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-024-01987-x","article-title":"Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial","volume":"9","author":"Dou","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.cpt.2025.12.001_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/bjh.14331","article-title":"Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies","volume":"176","author":"Li","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpt.2025.12.001_bib16","first-page":"825","article-title":"1994 Consensus conference on Acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.12.001_bib17","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR task force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.12.001_bib18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.cpt.2025.12.001_bib19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.12.001_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.12.001_bib21","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2025.12.001_bib22","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpt.2025.12.001_bib23","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.3390\/cancers12113132","article-title":"Ruxolitinib-associated infections in polycythemia vera: review of the literature, clinical significance, and recommendations","volume":"12","author":"Sadjadian","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpt.2025.12.001_bib24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/apm.13472","article-title":"Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: an updated systematic review and meta-analysis","volume":"132","author":"Roca Mora","year":"2024","journal-title":"APMIS"},{"key":"10.1016\/j.cpt.2025.12.001_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3892\/mmr.2024.13163","article-title":"Essential contribution of the JAK\/STAT pathway to carcinogenesis, lytic infection of herpesviruses and pathogenesis of COVID-19 (Review)","volume":"29","author":"Li","year":"2024","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.cpt.2025.12.001_bib26","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1073\/pnas.96.16.9339","article-title":"The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK\/STAT activation leads to loss of BamHI-Q promoter activity","volume":"96","author":"Chen","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cpt.2025.12.001_bib27","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2025.12.001_bib28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.25376","article-title":"Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results","volume":"94","author":"Gonz\u00e1lez Vicent","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpt.2025.12.001_bib29","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpt.2025.12.001_bib30","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","article-title":"The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers","volume":"51","author":"Shi","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.cpt.2025.12.001_bib31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/bmt.2013.235","article-title":"High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"49","author":"Gilis","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.12.001_bib32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-023-02155-5","article-title":"Rituximab for posttransplant lymphoproliferative disorder - therapeutic, preemptive, or prophylactic?","volume":"59","author":"Storek","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.12.001_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12935-021-01793-3","article-title":"Signaling pathways of EBV-induced oncogenesis","volume":"21","author":"Luo","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.cpt.2025.12.001_bib34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/vaccines9030288","article-title":"Factors associated with post-transplant active Epstein-Barr virus infection and lymphoproliferative disease in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis","volume":"9","author":"Enok Bonong","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cpt.2025.12.001_bib35","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00432-014-1742-z","article-title":"Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD","volume":"140","author":"Mensen","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.cpt.2025.12.001_bib36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3324\/haematol.2013.087338","article-title":"Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation","volume":"99","author":"Uhlin","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.cpt.2025.12.001_bib37","first-page":"138","article-title":"Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation (In Chinese)","volume":"37","author":"Bao","year":"2016","journal-title":"Chin J Hematol"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713225001156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713225001156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:52:18Z","timestamp":1778935938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713225001156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2949713225001156"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2025.12.001","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD)","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}